HCXY News and Press, Hercules Capital Inc. 6.25% Notes due 2033 From 05/06/22

The following slide deck was published by Hercules Capital, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Hercules Capital, Inc. 2022 Q1 - Results - Earnings Call Presentation

Hercules Capital, Inc. (HTGC) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Michael Hara – Investor Relations and Corporate Communications Scott Bluestein – Chief Executive Officer and Chief Investment Officer Seth Meyer – Chief Financial Of...

BIZD generated a steady yield of around 8% over the past 10 years. BIZD’s yield is sustainable as it invests in high yield generating stocks. Though BIZD’s stock performed poorly in the long run, it generated positive returns in the past one and three years, despite ...

Interest rates are finally starting to rise and this article discusses a sector that will benefit. HTGC is currently yielding 11.2% and higher interest rates will likely drive improved margins and dividend increases. More importantly, BDC pricing will likely head higher before add...

We take a look at the action in BDCs through the fourth week of February and highlight some of the key themes we are watching. The BDC sector was down marginally this week despite the support from higher short-term rates, flat to higher stocks and strong Q4 reporting. Two importan...

Hercules Capital, Inc. (HTGC) Q4 2021 Results Conference Call February 22, 2022 05:00 PM ET Company Participants Michael Hara - Managing Director, IR Scott Bluestein - CEO and CIO Seth Meyer - CFO Conference Call Participants Crispin Love - Piper Sander Kevin Fultz - JMP Securities Finian O'S...

BDCs continue to outperform in an inflationary and rising interest rate environment as investors prepare for higher rates that are accretive to BDC earnings to support higher dividends. Many equity REITs and most mortgage REITs have had negative stock price performance over the last 2...

Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications. Following the approval of Odevixibat in PFIC, Albireo needs to transform into a commercial company capable of generating profits. Albireo ...

Hercules Capital (NYSE:HTGC) (NYSE:HCXY) enters into a new $100M multi-currency credit facility with Sumitomo Mitsui Banking Corporation. The new credit facility also includes an uncommitted accordion feature expandable up to $150M. The interest rate applicable to borrowings un...

The following slide deck was published by Hercules Capital, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Hercules Capital, Inc. 2021 Q3 - Results - Earnings Call Presentation